Little is known about possible cryptic peptides of the recombinant growth hormone (somatropin). In this study, six synthetic somatropin-derived peptides (SDPs) were selected based on their sequences which correspond to the binding interface of the growth hormone receptor (GHR). Their novelty was confirmed by in silico and in vitro proteolytic digestion of somatropin. Chemical characterisation of the SDPs, i.e. identification via LC-MS and purity quantification via HPLC-UV and U(H) PLC-MRM, was first performed. All the SDPs were stable in brain tissue homogenate, liver tissue homogenate and serum (t 1/2 > 15 min). The metabolites in brain and serum, formed between 15 and 120 min, were also identified. The interactions towards the GHR and the human growth hormone binding protein (hGHBp) were also evaluated using GHR bioassay and native MS. No interaction was detected under the applied conditions. A last part of the study investigated the pharmacokinetics and tissue distribution of two peptides (i.e. SDP [167][168][169][170][171][172][173][174][175] and SDP 101-121 ), selected based on their position within somatropin. A high blood-brain barrier (BBB) influx was observed for SDP , while SDP 167-175 showed a negligible BBB influx. Based on the obtained results, the GHR binding of the selected SDPs is very low, requiring structural adaptations for further GHR-binding exploration.
Introduction
The human growth hormone (hGH), secreted from the pituitary gland into the bloodstream, circulates through the entire body exerting several endocrine functions (regulation of growth, development, and metabolism of target tissues). It can also act as an autocrine or paracrine factor in many extrapituitary tissues (Harvey 2010) . The hGH exerts its biological function directly by binding on the growth hormone receptor (GHR), which is ubiquitously distributed in the human body (Waters 2016) , as well as indirectly through the induced production of insulin-like growth factor (IGF) 1 (Gunawardane et al. 2015) . There is binding on two defined sites (i.e. site-I and site-II) on the GHR by at least four fragments within the hGH that represent the binding epitope: for site I, these are residues 41-68 and residues 167-175; for site II, these are residues 1-16 and residues 103-119 (Clackson and Wells 1995; Cunningham and Wells 1993; Sundström et al. 1996; De Vos et al. 1992) . Binding on both sites is essential for dimerization which results in activation of the associated JAK2 and Src family kinases (Elio et al. 2006; Waters 2016; Wells 1996) .
Somatropin (recombinant prepared hGH) as GHR agonist and pegvisomant (GHR antagonist) were developed for the treatment of pathologies like growth hormone deficiency syndrome and acromegaly, interfering with the growth of children and adults, emerged (Gunawardane et al. 2015; Ayuk and Sheppard 2006; Tritos and Biller 2017) . Due to the complex and multiple actions of hGH in target tissues and the involvement of the GHR, human growth hormone binding protein (hGHBp), and IGF 1, also other diseases and conditions can be associated to the hGH, like chronic liver disease or cirrhosis (Wallace et al. 2002; ClinicalTrials.gov 2018; Mahesh and Kaskel 2008) . hGH has also beneficial effects on memory, alertness, working capacity, and motivation. This indicates that hGH crosses the blood-brain barrier (BBB), acting on the central nervous system (CNS) (Nyberg 2000; Bracke et al. 2018; Pan et al. 2005) . In amyotrophic lateral sclerosis (ALS), GH insufficiency is observed, giving GH treatment the opportunity to be helpful due to its neuroprotective effects (Chung et al. 2015) . Moreover, there is increasing evidence that the GHR is overexpressed in several cancers (e.g. lung, pancreas, breast, skin) (Chhabra et al. 2018; Subramani et al. 2014; Gebre-Medhin et al. 2001; Sustarsic et al. 2013 ). As such, the growth hormone and its receptor become potential targets in the diagnosis and treatment of these neurological diseases and cancers.
Different isoforms of the hGH as a result of heterogeneity at the level of the growth hormone gene and due to posttranscriptional processing (Waters 2016; Gunawardane et al. 2015) , natural occurring metabolites, fragments, and segments are well-known, including their interaction with biological targets such as the GHR (Elio et al. 2006; De Vos et al. 1992; Wells 1996) . Cryptic peptides can be classified into three groups (Autelitano et al. 2006) , with the third group being peptides not endogenously expanded from their protein precursor, with a different or similar activity as their precursor. Therefore, due to the peptide advantages compared to proteins (Khanna 2012; Vlieghe et al. 2010) , we explored the potential of some cryptic somatropin-derived peptides (SDPs) as therapeutic/diagnostic compounds.
First, an autodock simulation of the SDPs to the GHR was done to assess the binding potential and to make an appropriate selection of the SDPs. Furthermore, the novelty of the SDPs was demonstrated by in silico and in vitro enzymatic somatropin digests. The second part of the study focussed on the biological activity of the selected SDPs. The hGHBp and GHR binding capacity and tissue distribution (including BBB transport) were characterised.
Materials and Methods

Chemicals, Reagents, and Equipment
Zomacton® 4 mg (Ferring, somatropin) was obtained from the University Hospital (Ghent, Belgium), hGHBp from MyBiosource (San Diego, USA), the SDPs (Table 1) Somatropin proteolytic digest analysis and identification of SDP metabolites was performed using a HPLC-UV-MS apparatus consisting of a Spectra System separations module, a Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) equipped with a Waters 2487 dual wavelength absorbance UV detector (Waters, Milford, USA) and Xcalibar 2.0 software (Thermo, San José, CA, USA) for data acquisition, as well as Thermo BioWorks software (San José, CA, USA) for protein identification. The purity analysis and in vitro metabolisation study was conducted on a HPLC-UV system equipped with a Waters Alliance 2695 separation module and a Waters 2996 PDA detector, with Empower 3 software for data handling (Waters, Milford, USA) . The metabolisation study of SDP 1-18,M+1-18,101-121 in serum was conducted on a U(H)PLC system directly coupled to a Waters Xevo TQ-S detector (both from Waters, Milford, USA), while SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] in serum was analysed with HPLC-UV system described above. Native MS studies were conducted on a Waters Synapt G2-Si high-resolution quadrupole time of flight (TOF) mass spectrometer (Waltham, MA) equipped with a LockSpray dual electrospray ion source. The PathHunter Cytosolic Tyrosine Kinase (CTK) assay with JAK2 target was from DiscoverX (Fremont, USA).
Autodock Simulations
Docking simulations were performed using AutoDock 4.2, release 4.2.3 (Morris et al. 2009 ). Different variations of position, global orientation, and conformation of the ligand (here the peptide/somatropin fragment) were simulated in search for plausible binding places in the protein target binding site (the extracellular part of the GHR). Bond lengths, angles, and the backbone of the peptide were kept rigid to limit the numbers of freedom. Only torsion angles in the peptide side chains were flexible. Rigid body docking was done, in which no degrees of freedom were allowed in the hGHBp target. The full conformational space was then sampled stochastically and interesting peptide conformations ('poses') were located by a genetic algorithm followed by a local refinement, based on an empirical free energy scoring function (Morris et al. 2009 ). The generated docked peptide-poses were then clustered on structural similarity, as measured by distance [root-mean square deviation (RMSD)] between poses. Highly populated clusters and clusters with low energy conformations were indicated as possible 'hits' and considered further.
In Silico Somatropin Digestion
The SitePrediction webtool (http://www.dmbr.ugent .be/prx/ bioit 2-publi c/SiteP redic tion/) was used to explore proteolytic cleavage sites in the GH substrate (Verspurten et al. 2009; Rawlings et al. 2004 ). Cleavage sites with > 95% specificity were reported.
In Vitro Proteolytic Digestions of Somatropin
The novelty of the selected SDPs was confirmed by proteolytic digestion (S-carboxymethylation of cysteine residues) of somatropin by trypsin, chymotrypsin, S. aureus V8 protease, PC1, PC2, and IDE were used following the method as previously reported in Bracke et al. (2014) . Digestion was performed at 37 °C while gently shaking at 300 rpm for the defined period of time in a thermomixer comfort (Eppendorf, Hamburg, Germany). 100 µL samples were taken after 0 h, 4 h, 24 h, 48 h and the reaction was stopped by addition of 20 µL formic acid (FA) to each sample. The samples were analysed by LC-MS as described in the peptide mapping section of reference (Bracke et al. 2014 ).
Metabolisation of the SDPs
The in vitro stability of the six SDPs was determined in serum, liver tissue homogenate, kidney tissue homogenate, and brain tissue homogenate according to standard protocols (Vergote et al. 2008; Svenson et al. 2010 ). The protein content of each homogenate was determined using the Pierce Modified Lowry Protein Assay method (Thermo Scientific) to generate a stock solution with a protein concentration of 0.6 mg/mL by dilution in Krebs-Henseleit buffer (KH) (pH 7.4, Sigma Aldrich). Briefly, 150 µL of a 1 mg/mL peptide solution, dissolved in KH buffer (pH 7.4) was added to 500 µL serum or tissue homogenate and incubated at 37 °C while shaking at 750 rpm. Aliquots of 100 µL were sampled after 0, 15, 30, 60, and 120 min of incubation into tubes containing an equal volume of trifluoroacetic acid (TFA) (1% V/V) in acetonitrile (ACN) and immediately subjected to 95 °C for 5 min, followed by flash cooling in an ice bath for 30 min. Finally, the samples were centrifuged at 20,000×g for 5 min at 5 °C prior to HPLC-UV (tissue homogenates of all SDPs and serum of SDP 39-70 , SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] , SDP 165-177 ) or U(H)PLC-MRM (serum of SDP 1-18 , SDP M+1-18, SDP 101-121 ) analysis. Blank control solutions were prepared as described above, without addition of peptide.
The half-life was determined as:
with the slope derived from the curve of the natural logarithm of the percentage of the amount at the start of the incubation, i.e. t = 0 min, versus time. Because of our interest in the passage through the BBB (see further), the formed metabolites during incubation of the peptides in serum or brain homogenate were identified. Time points were chosen between approximately one or two half-lives as determined in the kinetic evaluation. In case of a half-life of > 120 min, t 120 min was chosen as time point for metabolite identification.
HPLC-UV Analysis
The SDPs in tissue homogenates and SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] in serum were separated on a Vydac Everest C 18 column (4.6 × 250 mm, 5 µm) with suitable guard column (Grace, Lokeren, Belgium). The column was thermostated at a temperature of ± 40 °C. The injection volume was 20 µL, the flow was 1 mL/min. Mobile phase A consisted out of 0.1% (V/V) TFA in 95/5 (V/V) H 2 O/ACN, mobile phase B consisted out of 0.1% (V/V) TFA in 5/95 (V/V) H 2 O/ACN. The linear gradient program started with a 2 min isocratic hold at 100% A, followed by a linear gradient to 60% A and 40% B at 32 min. The column was rinsed with 100% B, followed by returning to the initial conditions and re-equilibration, giving a total run time of 50 min. UV detection was performed from 190 to 400 nm, with quantification at 210 nm.
(1)
U(H)PLC-MRM Analysis
Sample preparation: the peptides SDP 1-18,M+1-18,101-121 were analysed simultaneously, i.e. in the same serum sample. The in vitro metabolisation was performed as described in "Materials and Methods" section, with sampling adapted to 100 µL of sample added to 300 µL ACN and 0.1% TFA. Prior to injection, the samples were diluted in a novel antiabsorption diluent (BE2017/0040) to prevent adsorption to glass vials, by diluting 12 µL supernatant ad 2.0 mL diluent (i.e. 100 ng/mL). U(H)PLC-MRM mass spectrometry method: a 2.1 × 100 mm reverse phase column (Waters, Acquity UPLC BEH C18, 1.7 µm) maintained at 45 ± 5 °C was used for separation by a U(H)PLC system directly coupled to a Waters Xevo TQ-S detector. A 2.0 µL sample was injected at a flow rate of 0.5 mL/min. The gradient program was as follows [A: 90/5/5 H 2 O/ACN/DMSO (dimethylsulfoxide) containing 0.1% (m/V) FA and B: 5/90/5 H 2 O/ACN/DMSO containing 0.1% (m/V) FA]: isocratic phase of 100% A was maintained for 1.5 min, followed by a linear gradient over 5 min to 40% A (V/V) + 60% B (V/V). After the elution at 6.5 min, the column was washed with a 100% B flush and reverted to the initial state. The run was terminated after 15 min. The MS unit was operated in electrospray positive ionisation mode. Nitrogen was used as the nebulising gas and argon as the collision gas. Instrument settings were as follows: source and desolvation temperature, 500 °C each; cone and desolvation gas flow, 150 and 1000 L/h resp. Acquisition was performed in the multiple reaction monitoring (MRM) mode and monitored from 1.5 to 6.5 min (< 1.5 min and > 6.5 min to waste). Cone and capillary voltage, collision energy and mass transitions are given in Table 2 . Data were acquired using MassLynx software (V4.1 SCN 843, Waters, Milford, MA, USA).
Native MS
The native MS method was essentially similar as previously described (Bracke et al. 2017) : the non-denaturing MS data of standards (i.e. single peptides/proteins: all SDPs and hGHBp) and complex samples (i.e. a mixture of all six SDPs and hGHBp) were acquired in positive mode (ESI + ). A concentration of 666 nM for SDPs and 365 nM for hGHBp, dissolved in 25 mM ammonium acetate solution (pH 6.8-7.0) was used. Standards and samples were injected (10 µL) at a flow rate of 10 µL/min. The conditions of analysis were as follows: the source temperature was set at 150 °C, desolvation gas temperature was 300 °C, cone gas flow was 150 L/h, desolvation gas flow was 800 L/h, capillary voltage was 2.5 kV, and sampling cone voltage was 50.0 kV. Data were acquired between a m/z of 500 and 5000 Da.
In Vitro GHR Bio-assay
The PathHunter Cytosolic Tyrosine Kinase (CTK) Functional Assay (JAK2 target) was used for the profiling of the SDPs in agonist and antagonist format (Bracke et al. 2017 each well and incubated for 3 h. In antagonist mode, cells were pre-incubated with peptide for 60 min at 37 °C, followed by hGH agonist (EC 80 challenge, 0.012 µg/mL hGH) incubation for 3 h. For the peptides, a concentration range between 0.5 nM and 10 µM was evaluated. Assay signal was generated through a single addition of 12.5 or 15 µL (50% V/V) of PathHunter Detection reagent cocktail for agonist and antagonist assays resp., followed by 1 h incubation at room temperature.
In Vivo Tissue Distribution and the Blood-Brain Barrier Permeability
Female, Institute for Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice of age 7-10 weeks and weighing 23-32 g, were obtained from Envigo RMSB.V. (Venray, The Netherlands). The animal experiments were approved by our institute (Ghent University, Faculty of Veterinary Medicine, approval number EC2014/128). Experiments were Multiple time regression analysis and capillary depletion were performed as described by Bracke et al. (2018) .
Statistics
Regression lines were computed using the least squares method. Regression lines were statistically compared using Prism 5 software (Graphpad, La Jolla, USA).
Results
Selection of Somatropin-Derived Peptides
Docking simulations were performed for each of the four core peptide fragments (corresponding to the four fragments of the hGH that constitute the binding epitope) to the extracellular part of the receptor. In these docking simulations, relying on a genetic and local search algorithm, global position and orientation of the peptide, as well as side chain conformations were exhaustively sampled in search for a peptide pose with optimal binding position on the GHR (Fig. 1) .
The docking simulations predicted only favourable binding potential to the GHR for peptide 167-175. All other peptides were predicted to have unfavourable, positive binding energies with the GHR. In addition, peptides 1-16 and 103-119 interact mostly with the GHR in another location than the active site-I or -II. No meaningful clustering of poses was obtained from the ensemble of structures generated by docking simulations on peptide 41-68, thus in silico, this peptide did not interact with the receptor. For peptide 167-175, on the other hand, several clusters were successfully identified in the ensemble of the simulated docking poses. The poses had negative, favourable binding energies going from − 1 to − 3 kcal/mol and bounded either one of the symmetry-equivalent protein active sites. This peptide has in silico binding potential to the GHR.
Each peptide which represented the binding interface to the receptor, was selected with additionally one or two amino acids (based on the somatropin sequence) to the left and right of the fragment to offer the "core" more structural integrity and protection against exopeptidases (Table 1) . For the N-terminal fragment (SDP 1-18 ), an additional N-terminal methionine was included (SDP M+1-18 ). For fragment 167-175, which was predicted as most promising peptide binder, we selected the sequence as such ) and with additional residues on the left and the right (SDP [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] ). SDP 101-121 represents residues 103-119 with two additional amino acids on both ends.
The selected peptides were verified for their novelty. The proteolytic digestions of somatropin with trypsin, chymotrypsin, S. aureus V8, IDE, PC1, and PC2 did not Fig. 2 In silico cleavage site prediction on GH from typical proteases/peptidases in blood, kidney, and liver generate the proposed SDPs as metabolites. Moreover, in silico proteolytic digest by protease/peptidase enzymes (Werle and Bernkop-Schnürch 2006) on the somatropin sequence was performed, resulting in many possible predicted cleavage sites (Fig. 2) . Cleavage hotspots, here defined as more than three potential cleavage sites for a potential peptide bond, were R8-L9, R19-L20, Q22-L23, C33-A34, Q40-K41, R77-I78, R94-S95, K115-D116, R127-L128, R134-T135, R178-I179, and R183-S184. These cleavage hotspots, together with the GH-cleavage hotspots reported in literature show that the selected peptides are not likely to be metabolites from somatropin, emphasizing their novelty.
The six selected peptides were controlled for their identity and purity (SI 1). MS and MS 2 spectra confirmed the identity of the SDPs. All SDPs were found to have a purity of 95% or more except for SDP .
Metabolisation of the SDPs
The in vitro metabolisation was investigated in brain, liver, and kidney tissue homogenates, as well as in mouse serum (Vergote et al. 2008; Werle and Bernkop-Schnürch 2006) . SDP 1-18,M+1-18,101-121 co-eluted with serum bulk components, which made the quantification using UV (at 210 nm) unreliable. For these three peptides in serum matrix, a MRM mass spectroscopic method was used. Further identification of the metabolites was performed to confirm the stability of the core of the SDPs. The analytical recovery was always above 90% (see SI 3).
Metabolisation Kinetics
In general, a peptide is considered stable if more than 90% of the original peptide is found at the time point of 120 min relative to t 0 min for serum or a tissue homogenate. In that case, the minimum half-life was calculated using the 90% value considering a first-order kinetic. The half-lives of the SDPs are presented in Table 3 .
The half-lives in mouse brain homogenate ranged from 2.42 h for SDP 39-70 and 7.31 h for SDP M+1-18 , to more than 13 h for SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] , SDP 1-18 , and SDP . Comparable values were seen in mouse liver homogenate. For the kidney homogenate, the peptides were less stable with half-lives ranging between 9.12 and 48.57 min. In the kidney, many peptides are filtered by the glomerulus, degraded and excreted. Also for GH, the kidney is the main excretion site (Rigamonti et al. 2012) . For serum, SDP 101-121 had a half-life of more than 13 h, while the half-life of the other five SDPs was shorter (Table 3) .
Identification of Metabolites
For serum and brain, the metabolites were further identified to verify the stability of the receptor interaction "hotspots". Identified metabolites are given in Table 4 , with the parent peptide in bold and the major metabolite underlined. SDP 101-121 was stable: no metabolites were detected after 2 h confirming the high stability in brain and serum as already observed in the kinetic evaluation. SDP 39-70 has a major cleavage site at the peptide bond before and after F54 (i.e. the amino acid at position 54 within somatropin, Table 1 ), which was not a known cleavage site based on the in silico data and literature. The other SDPs contain several cleavage sites in their sequence. The major cleavage site for SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] and SDP 165-177 is the same: after the first lysine residue.
GH Receptor Binding Study of Selected Somatropin-Derived Peptides
Bioassay
The PathHunter Cytosolic Tyrosine Kinase (CTK) functional GHR bioassay was used to evaluate the functionality of the six SDPs for binding the human GHR and for activating/inhibiting the signal transduction cascade (SDP concentrations between 0.5 nM and 10 µM). Based on the dose response curves (Fig. 3) , none of the SDPs showed biological activity at a concentration of 10 µM or lower compared to the positive control, i.e. human GH for agonist mode and INCB018424 in antagonist mode being a potent, selective inhibitor of JAK1 and JAK2. The positive controls were given the maximum activity which can be reached and were set equal to 100%. It is thus concluded that there is no significant formation of a functional receptor dimer for JAK2 signaling (full agonist) or inhibition of functional receptor dimerization (full antagonist) under the applied conditions.
Native MS
The molecular interaction of the SDPs to the hGHBp was further investigated using native MS. Native MS, also called non-denaturing MS, of the peptide, the receptor (i.e. hGHBp) and the peptide combined with the receptor mixture was used. The results are given in Fig. 4 . For all SDPs, no signals for a peptide:hGHBp complex were detected, as well as no significant decrease in free hGHBp responses (all still between 92 and 118%) was observed in the mixture samples compared to the single peptide/protein samples.
Additional binding experiments were performed with a surface acoustic wave biosensor towards the hGHAb for further biological characterisation. The results are represented in SI 4.
Tissue Distribution
The in vivo tissue distribution was evaluated for the two most metabolically stable SDPs. Therefore, the peptides were radiolabeled with 125 I (SI 2). Figure 5 visualizes the tissue distribution of the radiolabeled peptides SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] and SDP 101-121 at 15 min after injection. SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] are predominantly found in serum and in lesser extent in the kidney. The design of the BBB is as such that almost no drugs or radiopharmaceuticals can enter in order to protect the brain against toxic agents (Pardridge 2012) . However, SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] and SDP 101-121 showed brain uptake.
Therefore, the brain tissue distribution of SDP 167-175 and SDP 101-121 was evaluated in more detail. A positive control (i.e. dermorphin) and a negative control (i.e. BSA) were included (Van Dorpe et al. 2012) . SDP 101-121 showed a very pronounced influx with K in = 1.43 µL/(g min) (Table 5 ; Fig. 6 ), which is significantly higher than somatropin and NOTA-modified somatropin (Bracke et al. 2018) . The K in value of SDP 167-175 was only 0.13 µL/(g min). The initial distribution volume (V i ) of SDP 101-121 is 25 µL/g which is higher than the V i of SDP 167-175 (i.e. 11 µL/g). Based on the peptide classification of Stalmans et al. (2015) , SDP 101-121 has a high influx while SDP 167-175 has a low influx and is not significantly different from BSA.
Discussion
Cryptic peptides can have bioactivities which are similar or totally different from their parent protein or prohormone (Autelitano et al. 2006; Baker et al. 2005) . These cryptic peptides expand the medicinal landscape because smaller compounds with an activity depending on the need could be generated. In SI 5, the currently known, natural, and smaller fragments of the hGH are listed, indicating the prohormone potential of the hGH and its receptor, the GHR. The selected SDPs are novel since they are not reported in literature or experimentally observed as metabolites. None of the SDPs resulted in an agonistic or antagonistic GHR cellular response under the selected conditions. To further evaluate binding of the SDPs on the receptor, native MS was conducted. The K D of hGH for hGHBp (1:1 complex) is reported around 0.3 nM (Fuh et al. 1990) . During the native MS study, concentrations of 666 nM SDP were used, identical to the concentrations used for somatropin in native MS (Bracke et al. 2017) . At these SDP concentrations, no signals for a peptide:hGHBp complex were detected. Chemical characterization and metabolic stability of the peptides under investigation was also performed. High purities of peptides are required for functionality studies, since impurities can lead to a biofunctional response leading to false positive or negative outcomes (Verbeken et al. 2012) . All peptides had LC-based purities over 90%. Because no degradation peaks were observed and half-lives were longer than 15 min (except for the kidney), all peptides were considered as metabolically stable.
Investigation of the pharmacokinetics of the peptides through the BBB was performed because the BBB forms a barrier during the development of effective therapies targeting diseases in the CNS (Pardridge 2005) . SDP 101-121 (K in of 1.43 µL/(g min)) belongs to the group of peptides with a medium to high BBB influx according Stalmans classification (Stalmans et al. 2015) . SDP [167] [168] [169] [170] [171] [172] [173] [174] [175] showed no significant influx compared to the vascular marker BSA, a protein which does not show BBB influx.
Conclusion
The aim of the study was to explore the potential of six SDPs as new diagnostic and/or therapeutic alternatives, selected based on the sequence which bind the site-I and site-II of the GHR. The purity of the peptides was chemically characterised and found to be more than 95%, except for SDP (90% purity). The metabolic stability was evaluated looking at the recovery and appearance of degradation peaks. The possible metabolites and metabolisation kinetics in brain, kidney, liver, and serum was evaluated. In brain, liver tissue homogenates, and serum, all peptides were found stable (t 1/2 > 15 min). In kidney tissue homogenates, shorter half-lives were observed. For all SDPs, except SDP 101-121 , 
